化合物 Pemirolast|T60289|TargetMol

價格	￥10600	￥17500	￥13800
包裝	25mg	100mg	50mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 Pemirolast	英文名稱:Pemirolast
CAS:69372-19-6	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Shipping with blue ice.
產(chǎn)品類別: 抑制劑
貨號: T60289

Product Introduction

Bioactivity

Name	Pemirolast
Description	Pemirolast is an orally active antiallergic agent. Pemirolast attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides, that can be used for bronchial asthma and conjunctivitis research [1] - [5].
In vitro	Pemirolast (1 μM-1 mM) inhibits A23187-induced LTC4 and ECP release from the eosinophils in a dose-dependent manner [1]. Pemirolast (0.1 mM and 1 mM) also inhibits PAF-induced and FMLP-induced ECP release from the eosinophils [1]. Pemirolast alleviates the activation of human eosinophils to inhibit granule protein LTQ and ECP release, so that alleviates controlling allergic diseases [1]. Pemirolast (100 nM-1 mM; 1-15 min) fails to significantly inhibit histamine release from human conjunctival mast cells [2]. Pemirolast (0.1 μg/mL-0.01 mg/mL) inhibits the activation of signal transduction phospholipases C and AZ in rat peritoneal mast cells, by inhibiting the degranulation reaction of antigen and compound 48/80, suppressing the formation of 1,2-diacylglycerol and phosphatidylic acid [3].
In vivo	Pemirolast potently reduces paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats [4]. Pemirolast (0.1-1 mg/kg; i.v.) inhibits taxel-induced pulmonary vascular hyperpermeability, and reverses paclitaxel-induced arterial PaO2 decreasing at a dosage of 1 mg/kg, 30 minutes after paclitaxel injection (15 mg/kg; i.v.) [4]. Pemirolast (1 mg/kg; i.v.) reverses taxel-induced elevation of the concentrations of sensory neuropeptides (CGRP, substance P and neurokinin A), 30 minutes after paclitaxel injection (15 mg/kg; i.v.) [4]. Pemirolast (10 mg/kg/d; p.o.; 4-5 d) significantly reduces cisplatin-induced kaolin intake on days 3 and 4 and inhibits cisplatin-induced substance P release in the cerebrospinal fluid (CSF) in rats [5]. Animal Model: Male Wistar rats (6-week-old, 160-250 g) [5] Dosage: 10 mg/kg Administration: Oral gavage; 5 days: 1 h or 30 min before and 24, 48, 72 and 96 h (five times in total) after administration of cisplatin (2-10 mg/kg; i.v.) Result: Inhibited the cisplatin-induced increase in kaolin intake on days 3 and 4, without decreasing in normal feed intake. Animal Model: Male Wistar rats (6-week-old, 160-250 g) [5] Dosage: 10 mg/kg Administration: Oral gavage; 4 days: 30 min before and 24, 48, 72 and 96 h (four times in total) after administration of cisplatin (5 mg/kg; i.v.). Result: Significantly reversed the cisplatin-induced increase of substance P levels to vehicle levels in the CSF.
Storage	Shipping with blue ice.

關(guān)鍵字： Pemirolast|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計算機(jī)輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊資本	566.265100萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場三路238號8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

甲強(qiáng)龍琥珀酸鈉|T0294|TargetMol

￥283

化合物 Haloperidol hydrochloride|T21669|TargetMol

￥10600

地托咪定|T22719|TargetMol

￥10600